Bausch Health Companies Inc. (TSX:BHC)
Canada · Delayed Price · Currency is CAD | Market Cap | 2.97B -28.0% |
| Revenue (ttm) | 13.97B +5.9% |
| Net Income | 504.23M |
| EPS | 1.35 |
| Shares Out | n/a |
| PE Ratio | 5.90 |
| Forward PE | 1.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 318,554 |
| Average Volume | 534,236 |
| Open | 7.89 |
| Previous Close | 7.84 |
| Day's Range | 7.86 - 8.05 |
| 52-Week Range | 5.91 - 11.97 |
| Beta | 0.37 |
| RSI | 36.31 |
| Earnings Date | Feb 18, 2026 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews
Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention
Bausch Health's turnaround could pay off for value investors patient enough to wait for it.
Bausch (BHC) Faces Legal Settlement Over Generic Drug Price Fixing
Bausch (BHC) Faces Legal Settlement Over Generic Drug Price Fixing
Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor
Bausch Health Companies Inc. was hit by a failed RED-C Phase 3, weak cash flow vs. interest, and a risky pipeline. Click for more on BHC stock as it sells off.
Bausch Health (BHC) Faces Setback with Phase 3 Trial Results
Bausch Health (BHC) Faces Setback with Phase 3 Trial Results
Bausch Health Companies Becomes Oversold (BHC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Stocks making the biggest moves midday: Fortinet, Moderna, Intel, Bausch Health & more
These are the stocks posting the largest moves in midday trading.
Bausch Health Companies (BHC) Shares Cross Below 200 DMA
In trading on Friday, shares of Bausch Health Companies Inc (Symbol: BHC) crossed below their 200 day moving average of $6.28, changing hands as low as $5.90 per share. Bausch Health Companies Inc sha...
Bausch Health (BHC) Falls as Phase 3 Trials Miss Primary Endpoint
Bausch Health (BHC) Falls as Phase 3 Trials Miss Primary Endpoint
Bausch Health falls on phase 3 failure of liver disease complications drug
Bausch Health (BHC) Releases Phase 3 Trial Results for Liver Cirrhosis Treatment
Bausch Health (BHC) Releases Phase 3 Trial Results for Liver Cirrhosis Treatment
Bausch Health's brain dysfunction treatment fails late-stage trial
Bausch Health said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of a late-stage trial.
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
LAVAL, QC, Jan. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid...
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18,...
Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bausch Health Companies Inc. (BHC) 44th Annual J.P.
Bausch Health Companies Inc at JPMorgan Healthcare Conference Transcript
Bausch Health Companies Inc at JPMorgan Healthcare Conference Transcript
Bausch Health (BHC) Raises 2025 Revenue and EBITDA Guidance
Bausch Health (BHC) Raises 2025 Revenue and EBITDA Guidance
Bausch Health sets 2025 outlook at the higher end of the prior range
Bausch Health (BHCO) stock in focus as the company set its full-year 2025 guidance at the higher end of the previously announced range. Read more here.
Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
LAVAL, QC, Jan. 5, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Thomas J. Appio, Chief Executive Officer, will participate at the 44th Annual J.P.
Looking Into Bausch Health Companies Inc's Recent Short Interest
Bausch Health Companies Inc's (NYSE: BHC) short interest as a percent of float has risen 13.33% since its last report. According to exchange reported data, there are now 6.41 million shares sold shor...
Bausch Health Announces Final Results and Expiration of Exchange Offers
LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company, th...
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year
Strong operating results did not stop one fund from walking away entirely, raising questions about how much patience volatile healthcare names really command.
Bausch Health’s Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake
Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence.
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the results to date of its previously announced offers to exchange the...
John Paulson's Strategic Acquisition in Bausch Health Companies Inc.
John Paulson's Strategic Acquisition in Bausch Health Companies Inc.